These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 8369168

  • 1. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients.
    Funkhouser A, Clements ML, Slome S, Clayman B, Viscidi R.
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):627-32. PubMed ID: 8369168
    [Abstract] [Full Text] [Related]

  • 2. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
    Lambert JS, Viscidi R, Walker MC, Clayman B, Winget M, Wolff M, Schwartz DH.
    Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
    [Abstract] [Full Text] [Related]

  • 3. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
    Gorse GJ, Frey SE, Newman FK, Belshe RB.
    J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
    [Abstract] [Full Text] [Related]

  • 4. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G.
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [Abstract] [Full Text] [Related]

  • 5. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB.
    Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
    [Abstract] [Full Text] [Related]

  • 6. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC, Graham BS, Belshe RB, Schwartz D, Corey L, Bolognesi DP, Stablein DM, Montefiori DC, McElrath MJ, Clements ML.
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [Abstract] [Full Text] [Related]

  • 7. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ, Corey L, Patel GB, Mandava M, Hsieh RH, Matthews TJ, Walker MC, McElrath MJ, Berman PW, Eibl MM, Belshe RB.
    AIDS Res Hum Retroviruses; 1999 Jan 20; 15(2):115-32. PubMed ID: 10029244
    [Abstract] [Full Text] [Related]

  • 8. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
    Pialoux G, Hocini H, Pérusat S, Silberman B, Salmon-Ceron D, Slama L, Journot V, Mathieu E, Gaillard C, Petitprez K, Launay O, Chêne G, ANRS VAC14 Study Group.
    Vaccine; 2008 May 19; 26(21):2657-66. PubMed ID: 18068876
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC, Graham BS, Kliks S, Wright PF.
    J Clin Immunol; 1992 Nov 19; 12(6):429-39. PubMed ID: 1287035
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Quantification of IgA and IgG and specificities of antibodies to viral proteins in parotid saliva at different stages of HIV-1 infection.
    Cartry O, Moja P, Quesnel A, Pozzetto B, Lucht FR, Genin C.
    Clin Exp Immunol; 1997 Jul 19; 109(1):47-53. PubMed ID: 9218823
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160.
    Vasudevachari MB, Uffelman KW, Kovacs J, Yeh CK, Lane HC, Salzman NP.
    J Acquir Immune Defic Syndr (1988); 1992 Jul 19; 5(8):817-21. PubMed ID: 1517967
    [Abstract] [Full Text] [Related]

  • 17. Salivary antibodies to human immunodeficiency virus type 1 in a phase I AIDS vaccine trial.
    Archibald DW, Hebert CA, Sun D, Tacket CO.
    J Acquir Immune Defic Syndr (1988); 1990 Jul 19; 3(10):954-8. PubMed ID: 2204698
    [Abstract] [Full Text] [Related]

  • 18. Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients.
    Raux M, Finkielsztejn L, Salmon-Céron D, Bouchez H, Excler JL, Dulioust E, Grouin JM, Sicard D, Blondeau C.
    J Immunol Methods; 1999 Jan 01; 222(1-2):111-24. PubMed ID: 10022378
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients.
    Moja P, Tranchat C, Tchou I, Pozzetto B, Lucht F, Desgranges C, Genin C.
    J Infect Dis; 2000 May 01; 181(5):1607-13. PubMed ID: 10823760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.